CoChat

Placebo-Controlled Trial of Cytisine for Smoking Cessation

Open access
West, Robert, Zatonski, Witold, Cedzynska, Magdalena, Lewandowska, Dorota, Pazik, Joanna, Aveyard, Paul, Stapleton, John · 2011 · New England Journal of Medicine

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cytisine, a partial agonist that binds with high affinity to the α(4)β(2) nicotinic acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking cessation. This study assessed the efficacy and safety of cytisine as compared with placebo. METHODS: We conducted a single-center, randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive cytisine or matching placebo for 25 days; participants in both groups received a minimal amount of counseling during the study. The primary outcome measure was sustained, biochemically verified smoking abstinence for 12 months after the end of treatment. Of 1542 adult smokers screened, 740 were enrolled and 370 were randomly assigned to each study group. RESULTS: The rate of sustained 12-month abstinence was 8.4% (31 participants) in the cytisine group as compared with 2.4% (9 participants) in the placebo group (difference, 6.0 percentage points; 95% confidence interval [CI], 2.7 to 9.2; P=0.001). The 7-day point prevalence for abstinence at the 12-month follow-up was 13.2% in the cytisine group versus 7.3% in the placebo group (P=0.01). Gastrointestinal adverse events were reported more frequently in the cytisine group (difference, 5.7 percentage points; 95% CI, 1.2 to 10.2). CONCLUSIONS: In this single-center study, cytisine was more effective than placebo for smoking cessation. The lower price of cytisine as compared with that of other pharmacotherapies for smoking cessation may make it an affordable treatment to advance smoking cessation globally.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1102035

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 25 references

Research works printed but not linked: 5

  1. Cahill K, 2010, Cochrane Database Syst Rev, 12, CD006103
  2. Stead LF, 2008, Cochrane Database Syst Rev, 1, CD000146
  3. Hughes JR, 2007, Cochrane Database Syst Rev, 1, CD000031
  4. Tutka P, 2006, Pharmacol Rep, 58, 777
  5. Stoyanov S, 1965, Chimpharm Sofia, 2, 13

Cited by

Items 201–234 of 234

Metadata

Authors
West, R., Zatonski, W., Cedzynska, M., Lewandowska, D., Pazik, J., Aveyard, P., & Stapleton, J.
Affiliations
  • Cancer Research UK (GB)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • University of Birmingham (GB)
Venue
New England Journal of Medicine
Published
2011-09-29
Volume
365
Issue
13
Pages
1193-1200
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2023431702
Cited by
234
References
25
Citations by year
2026: 14 · 2025: 11 · 2024: 13 · 2023: 11 · 2022: 21 · 2021: 13 · 2020: 9 · 2019: 10 · 2018: 16 · 2017: 10 · 2016: 11 · 2015: 14 · 2014: 16 · 2013: 28 · 2012: 28
FWCI
17.19
Type
journal article
Language
en
Licence
other-oa
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Funders
  • Cancer Research UK
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
cytisine, smoking cessation, nicotine dependence, nicotinic acetylcholine receptors, smoking abstinence, pharmacotherapy, gastrointestinal adverse effects, low-cost treatment
MeSH terms
Adult, Cystine, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Placebos, Smoking Cessation, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.